Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H12I3N2O2.Na |
| Molecular Weight | 619.9391 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CN(C)C=NC1=C(I)C=C(I)C(CCC([O-])=O)=C1I
InChI
InChIKey=ZFHZUGUCWJVEQC-UHFFFAOYSA-M
InChI=1S/C12H13I3N2O2.Na/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19;/h5-6H,3-4H2,1-2H3,(H,18,19);/q;+1/p-1
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C12H12I3N2O2 |
| Molecular Weight | 596.9493 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Iopanoic acid and ipodate salts have been used for oral cholangiography to visualize the biliary ducts. Ipodate salts have been used for the long-term treatment of Graves' disease and in hyperthyroidism. Ipodate reduced levels of T3 and T4 in the patients. Ipodate also inhibits the conversion of T4 to T3. It is not considered a first-line approach. Ipodate sodium lacks FDA approval for these uses. During investigation of mechanism of action was discovered, that binding of sodium ipodate with nuclear T3 receptors was not a prominent mechanism via which the drug attenuates T3 effects in vivo. Sodium ipodate could enhance T3 effects at the cellular level and that enhancement could not be reflected by routinely monitored serum TSH.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
250 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5045427/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
IPODIC ACID blood | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1600 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5045427/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
IPODIC ACID blood | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5045427/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
IPODIC ACID blood | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. | 2007-06 |
|
| Use of oral cholecystography agents in the treatment of hyperthyroidism of subacute thyroiditis. | 2003-03 |
|
| The use of oral radiographic contrast agents in the management of hyperthyroidism. | 2001-06 |
|
| A study of cardiac effects of thyroid hormones: evidence for amelioration of the effects of thyroxine by sodium ipodate. | 1984-06 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:46:13 GMT 2025
by
admin
on
Mon Mar 31 17:46:13 GMT 2025
|
| Record UNII |
F316LLW9WW
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QV08AC08
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
||
|
WHO-ATC |
V08AC08
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
||
|
NCI_THESAURUS |
C1937
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000077382
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY | |||
|
1221-56-3
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201243
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY | |||
|
F316LLW9WW
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY | |||
|
1033
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY | |||
|
DTXSID9048271
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY | |||
|
C65954
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY | |||
|
214-945-3
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY | |||
|
DBSALT001318
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY | |||
|
SUB14256MIG
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY | |||
|
9887
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY | RxNorm | ||
|
23671932
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY | |||
|
m6385
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY | Merck Index | ||
|
106962
Created by
admin on Mon Mar 31 17:46:13 GMT 2025 , Edited by admin on Mon Mar 31 17:46:13 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |